Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07064005 · ClinicalTrials.gov registry record · Phase 1
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
A Phase 1 study of Parkinsons Disease (PD), sponsored by Pravat Mandal.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07064005 is a Phase 1 study of Parkinsons Disease (PD) that is actively recruiting participants, run by Pravat Mandal. The registered enrollment target is 12 participants, below the 119-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07064005, a Phase 1 study of Parkinsons Disease (PD), is actively recruiting participants, sponsored by Pravat Mandal.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation. 2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation 3. To study impact of GGC on gut health on the PD patients.
Conditions Studied
Interventions
- DRUG Gamma- glutamylcysteine
Study Locations (1)
Pennsylvania
- UPMC Presbyterian Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-03-20 |
| Est. Completion | 2027-11-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07064005
The ClinicalTrials.gov registry entry for NCT07064005 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (90% lower). The listed sponsor is Pravat Mandal, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinsons Disease (PD) appearing as the primary indexed condition, and to 1 intervention - of which Gamma- glutamylcysteine is the first listed.
NCT07064005 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07064005 about?
NCT07064005 is a clinical study titled "Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.". This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to b...
What is the current status of trial NCT07064005?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-03-20. Estimated completion is 2027-11-27.
What conditions does trial NCT07064005 study?
This clinical trial studies the following conditions: Parkinsons Disease (PD).
What interventions are being tested in trial NCT07064005?
The interventions under investigation include: Gamma- glutamylcysteine (DRUG).
Who is sponsoring clinical trial NCT07064005?
This trial is sponsored by Pravat Mandal, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07064005 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsons Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
COMPLETED · Phase 1
-
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
COMPLETED · Phase 1
-
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
COMPLETED · Phase 1
-
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
RECRUITING · NA
-
A Study of NE3107 in Early Parkinson's
RECRUITING · Phase 2
-
Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.